Kiniksa Pharmaceuticals International (KNSA) Research & Development (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Research & Development came in at $40.9 million in Q2 2026, up 118.09% YoY from $18.8 million in Q2 2025, and up 48.86% on a QoQ basis from $27.5 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Research & Development (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Research & Development data on file, last reported at $40.9 million in Q2 2026.
- Quarterly Research & Development rose 118.09% year-over-year to $40.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $127.1 million (up 31.05% YoY) and the FY2025 annual result came in at $96.9 million, down 13.23% from the prior year.
- Research & Development climbed to $40.9 million in Q2 2026, from $27.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $40.9 million in Q2 2026 to a low of $13.8 million in Q2 2022.
- A 5-year average of $23.1 million and a median of $22.3 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development sank 47.54% — and 2026, when it soared 118.09%.
- Tracing KNSA's Research & Development over 5 years: stood at $14.4 million in 2022, then soared by 39.35% to $20.1 million in 2023, then surged by 75.62% to $35.2 million in 2024, then fell by 1.72% to $34.6 million in 2025, then grew by 18.17% to $40.9 million in 2026.
- The last three Research & Development figures came in at $40.9 million (Q2 2026), $27.5 million (Q1 2026), and $34.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.13 Bn | 5.60 Bn | 220.03 Mn | 40.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.90 Mn |
| Mar 31, 2026 | 27.48 Mn |
| Dec 31, 2025 | 34.61 Mn |
| Sep 30, 2025 | 24.17 Mn |
| Jun 30, 2025 | 18.75 Mn |
| Mar 31, 2025 | 17.00 Mn |
| Dec 31, 2024 | 35.22 Mn |
| Sep 30, 2024 | 26.06 Mn |
| Jun 30, 2024 | 24.02 Mn |
| Mar 31, 2024 | 26.33 Mn |
| Dec 31, 2023 | 20.05 Mn |
| Sep 30, 2023 | 17.11 Mn |
| Jun 30, 2023 | 23.77 Mn |
| Mar 31, 2023 | 15.17 Mn |
| Dec 31, 2022 | 14.39 Mn |
| Sep 30, 2022 | 16.49 Mn |
| Jun 30, 2022 | 13.80 Mn |
| Mar 31, 2022 | 20.82 Mn |
| Dec 31, 2021 | 27.43 Mn |
| Sep 30, 2021 | 19.24 Mn |